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Introduction: The International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory Society 
classification of lung adenocarcinoma recommends identification of 
pathologic patterns in metastatic samples where possible. We investi-
gated the clinical relevance of these patterns.
Methods: Patients with a surgical biopsy of lung adenocarcinoma 
from a metastatic site were included. Slides were reviewed by an 
anatomical pathologist identifying the histologic patterns of solid 
with mucin, acinar, micropapillary, papillary, and assigning a major 
adenocarcinoma subtype according to the International Association 
for the Study of Lung Cancer/American Thoracic Society/European 
Respiratory Society classification. EGFR and KRAS mutation 
testing were performed on formalin-fixed, paraffin-embedded blocks. 
Mutations were detected by high resolution melting assay with high 
resolution melting-positive samples confirmed by Sanger sequencing.
Results: One-hundred patients were included. The major histologic 
subtype prevalence was as follows: solid (50), acinar (29), micropap-
illary (20), and papillary (1). Of 100 patients, 45 received no systemic 
therapy with no overall survival differences seen by histologic sub-
type and 55 received systemic therapy (chemoradiotherapy with cura-
tive intent or palliative chemotherapy). Worse survival was seen in 
the major solid histologic subtype compared with major acinar (haz-
ard ratio 0.32 [95% confidence interval 0.15–0.68], p = 0.003) and 
micropapillary subtypes (hazard ratio 0.34 [95% confidence interval, 
0.17–0.69], p = 0.003). The major solid histologic subtype was less 
likely to harbor EGFR mutations (p = 0.006) and was less frequent in 
never smokers (p = 0.010) compared with other histologic subtypes.
Conclusion: The major solid histologic subtype of lung adenocar-
cinoma at metastatic sites is associated with shorter overall survival 
on systemic anticancer therapy. Furthermore, the major solid histo-
logic subtype is less likely to harbor EGFR mutations. These results 
require validation in larger cohorts.
Key Words: Metastatic lung adenocarcinoma, Histopathology, 
EGFR, KRAS.
(J Thorac Oncol. 2014;9: 654–663)
The morphologic heterogeneity of lung adenocarci-noma has long been recognized. The 2004 World Health 
Organization (WHO) Classification of Lung Tumors, which is 
recommended for use in reporting of resection specimens only, 
identified several different morphologic subtypes of lung ade-
nocarcinoma including acinar, papillary, and solid with mucin 
patterns and bronchioloalveolar carcinoma.1 Furthermore, the 
2004 WHO classification recommended that where more than 
one morphologic subtype was present in a tumor, it should 
be classified as adenocarcinoma of mixed subtype. Over time, 
it became clear that this diagnostic term, adenocarcinoma of 
mixed subtype, was of little clinical utility given that nearly 
95% of tumors fell under this definition.2
In 2011, a new classification for resected lung adeno-
carcinoma was proposed by the International Association 
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for the Study of Lung Cancer (IASLC), American Thoracic 
Society (ATS), and the European Respiratory Society 
(ERS).3 The IASLC/ATS/ERS classification built on pre-
vious pathologic studies that demonstrated subtypes with 
favorable and unfavorable patient outcomes after surgi-
cal resection for early stage disease. Multiple independent 
groups have demonstrated the superiority of the IASLC/
ATS/ERS classification over the WHO system in providing 
prognostic information in patients undergoing resection of 
early stage lung adenocarcinoma independent of pathologic 
stage,4–11 with only one group failing to demonstrate an 
association.12
In addition, for the first time, the new IASLC/ATS/ERS 
classification provided a classification scheme for reporting 
of lung cancer in small biopsies and cytology specimens. As 
part of this proposal, it is suggested that when lung adenocar-
cinoma is diagnosed in a small biopsy/cytology specimen, the 
pathologist should “describe (the) identifiable patterns pres-
ent.” Given that there is minimal evidence for this recommen-
dation, the authors of the new classification posed the research 
question: “In specimens from metastatic sites, is there any 
clinical significance to recognizing histologic patterns, includ-
ing the predominant pattern?”3
Previously, the distinction between the different sub-
types of non–small-cell lung carcinoma in metastatic disease 
had no bearing on treatment decisions. This has changed 
recently because of two major discoveries that have had a 
marked impact on clinical practice. First, patients with meta-
static squamous cell carcinoma (SqCC) have been found to 
be at risk of significant toxicity from bevacizumab caused 
by major hemorrhage.13 In addition, patients with metastatic 
squamous cell carcinoma had inferior survival outcomes, in 
comparison with those with adenocarcinoma and large cell 
carcinoma, when treated with pemetrexed-based chemother-
apy caused by high expression of thymidylate synthase.14,15 
Second, the prevalence of oncogenic driver mutations, some 
associated with targeted therapies, differs between adenocar-
cinoma16 and squamous cell carcinoma.17 Review of the litera-
ture reveals that only one group has investigated the impact 
of subtyping of adenocarcinoma in specimens from patients 
with unresectable lung adenocarcinoma, classifying tumors 
according to the 1981 WHO classification (the contemporary 
classification at the time of their study). In this work, the pres-
ence of particular adenocarcinoma subtypes had no impact on 
overall survival (OS).18,19
In this study, we aimed to explore the clinical relevance 
of subtyping adenocarcinoma in biopsy specimens from meta-
static sites in patients with metastatic lung adenocarcinoma, 
according to the new IASLC/ATS/ERS classification. We also 
examined the relationship of the adenocarcinoma subtypes to 
mutations in the epidermal growth factor receptor (EGFR) 
and KRAS genes.
MATERIALS AND METHODS
Patients
The Human Research and Ethics Committee at St. 
Vincent’s Hospital approved this study. A review of two pro-
spectively maintained clinical databases and associated tumor 
board meetings was conducted to identify patients who had had 
surgical sampling of lung adenocarcinoma from a metastatic 
site between 2000 and 2010. All patients had pathologically 
confirmed adenocarcinoma defined as a malignant epithelial 
tumor with histopathologic patterns including acinar, papil-
lary, micropapillary, and solid with mucin adenocarcinoma, 
defined according to the new IASLC/ATS/ERS classification.3 
Patients included with stage III disease underwent mediasti-
nal sampling for diagnosis and staging, but did not proceed to 
definitive surgical resection. All identified patients with stage 
IV lung adenocarcinoma underwent either surgical resection 
or sampling of a metastatic deposit. Clinical information was 
collected from the hospital medical records and records of 
treating medical oncologists and surgeons. The definition of a 
never smoker was a person with lifetime equivalent consump-
tion of fewer than 100 cigarettes.
Histologic Evaluation
In patients who had undergone multiple surgical pro-
cedures for metastatic disease, the case containing the largest 
amount of tumor tissue was chosen to allow sufficient tissue 
for EGFR and KRAS analyses. The size (recorded as the larg-
est dimension of a specimen in millimeters), location, and 
number of tumors were obtained from the pathology reports. 
A pathologist reviewed all hematoxylin and eosin (H&E) 
slides from each case. Patients were excluded at the time of 
pathologic review if the specimen was very small, if crush 
artifact was present precluding clear recognition of different 
adenocarcinoma patterns making it impossible to assign a 
major histologic pattern, or if there was insufficient available 
tissue for molecular testing.
The presence of different adenocarcinoma patterns, 
including acinar, papillary, micropapillary, and solid with 
mucin, as defined by the new IASLC/ATS/ERS classifica-
tion, was recorded as a binary variable. It was possible in each 
case to identify a major histologic pattern; however, it was not 
possible to assign percentages to the different histologic pat-
terns present. We chose to use the term “major” for the most 
prominent histologic pattern observed in metastatic samples. 
This term was used to avoid confusion with the recommenda-
tion of the new IASLC/ATS/ERS classification to use the term 
“predominant” for the most prominent histologic pattern iden-
tified in a resection specimen from the lung. All cases under-
went immunostaining with TTF1 (clone SPT24, NovoCastra, 
Newcastle Upon Tyne, United Kingdom).
Molecular Pathology
Deparaffinization and DNA extraction
A formalin-fixed, paraffin-embedded block with ade-
quate tumor for molecular analysis was chosen from each case, 
and a tumor-rich area was circled on the corresponding glass 
slide. This region was sampled from each block using two mm 
diameter dermatology core punches. The punched core tumor 
tissues were deparaffinized with 800 μl of xylene by incubat-
ing for seven minutes, followed by washings with 800 μl of 
100 and 70% ethanol. After removal of 70% ethanol, tumor 
tissues were incubated at 55°C for 15 minutes for removal 
of residual ethanol. Genomic DNA was extracted using the 
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DNeasy Tissue and Blood kit (Qiagen, Hilden, Germany) fol-
lowing the manufactures instructions with following modifi-
cations based on those of Wu et al.20 After addition of ATL 
buffer, tissues were heat treated at 98°C for 15 minutes, fol-
lowed by incubation at 56°C for 3 days after addition of 36 μl 
proteinase K (Worthington, NJ) at 20 mg/ml concentration.
EGFR and KRAS mutation testing
EGFR mutations in exons 18 to 21 and KRAS muta-
tions in codon 12 and 13 were scanned by high reso-
lution melting using the assay conditions previously 
described21,22 with the following modifications. EGFR ex19 
F 5′-TAACGTCTTCCTTCTCTCTCTGTC-3′ and EGFR 
ex19 R 5′-CCCACACAGCAAAGCAGAAACTC-3′ prim-
ers were used to amplify a shorter amplicon of 152 bp. To 
reduce sequence artifacts’ arising from uracil because of 
cytosine deamination in formalin-fixed, paraffin-embedded 
DNA,23 0.5 U of uracil-DNA glycosylase (New England 
Biolabs) and 0.5X of uracil-DNA glycosylase buffer was 
added to high resolution melting reaction that was prepared 
in a final volume of 20 μl. For uracil-DNA glycosylase treat-
ment, an incubation step at 37°C for 30 minutes was added 
before the standard polymerase chain reaction amplification. 
Samples were tested in duplicate, and all high resolution 
melting positives were sequenced using the conditions pre-
viously described.21
Statistical Analysis
Statistical analysis was undertaken using STATA ver-
sion 12 (Statacorp LP, TX). Survival analysis was performed 
using the Kaplan-Meier method with hazard ratios derived 
using the Cox Proportional Hazards model. Tests of associa-
tion were performed using Pearson’s χ2 or Fisher’s exact test 
as appropriate. Median times and hazard ratios are reported 
with their 95% confidence interval (CI). p less than 0.05 was 
considered statistically significant.
RESULTS
Patient and Tumor Characteristics
This data set of 100 patients, accrued from the years 
2000 to 2010, comprised 66% males, with a median age at 
diagnosis of 64 years (range, 36–86 years). At the time of anal-
ysis, 98 patients had died. The Eastern Cooperative Oncology 
Group (ECOG) performance status at diagnosis was 0 or 1 in 
69 patients and ≥ 2 in 31 patients. There were 21 never, 35 
current, and 44 former smokers.
In order of frequency, the site of tissue sampling was: 
brain (30%), pleura (25%), bone/skeletal muscle (20%), 
mediastinum (18%), and chest wall or supraclavicular fossa 
(7%). Fifty-two specimens were acquired at metastatectomy, 
43 specimens were acquired through open biopsy either as a 
diagnostic procedure or as part of a therapeutic procedure, and 
five specimens were core biopsies. The breakdown of speci-
men type by site together with the median size and size range 
of specimens is included in Table 1. Treatment was given to 
patients according to clinician assessment and in keeping with 
local management guidelines.
Fifteen of 100 (15%) patients presented with unresect-
able stage III disease at diagnosis and had tissue acquired from 
a diagnostic mediastinoscopy. Of these 15 patients, 10 received 
radiotherapy together with platinum doublet chemotherapy with 
curative intent (66%). One patient (6%) received palliative che-
motherapy with carboplatin/gemcitabine. Three patients (20%) 
received palliative radiotherapy without systemic therapy, and 
one patient (7%) received best supportive care only. Of the 15 
patients, 14 (93%) died as a result of their lung cancer. One 
patient remains alive at last follow-up of 82 months.
Eighty-five patients presented with stage IV disease at 
diagnosis. Of these, 44 patients (52%) received systemic therapy. 
Thirty-eight patients received first-line platinum doublet chemo-
therapy and three patients received single agent gemcitabine. 
Two patients had resection of an isolated central nervous sys-
tem metastasis followed by radiotherapy to the chest and com-
bined concurrent platinum doublet chemotherapy. One patient 
with an EGFR mutation in exon 18 (G719S) and concomitant de 
novo exon 20 mutation (T790M) received first line afatinib. One 
patient remains alive at last follow-up of 50 months.
For the 55 patients who received systemic anticancer 
therapy, the median number of lines of treatment was two 
(range one to five). Thirty-three patients received two or more 
lines of therapy. Patients with poor performance status were 
significantly less likely to receive systemic therapy (ECOG 
0–1: 43 of 69 [62%] versus ECOG ≥2: 12 of 31 [39%], 
χ2 [1] = 4.82, p = 0.028).
Examples of the major histologic patterns are shown 
in Figure 1. The most frequent major histologic pattern seen 
in the 100 metastatic lung adenocarcinoma tumors was solid 
with mucin at 50%, followed by acinar at 29% and micropap-
illary at 20%. Major papillary pattern was seen in one case 
only. The 100 tumors showed a range of different histologic 
patterns, with the number of different patterns observed in 
each specimen as follows: one pattern seen in 10% of cases; 
two patterns in 45%; three patterns in 33%; and four patterns 
in 12% of cases. The frequency of the different patterns pres-
ent in individual samples was as follows: solid seen in 82% 
of cases; micropapillary in 68%; acinar in 68%; and papil-
lary in 29% of cases. Major solid pattern was less common 
in patients who were never smokers when compared with for-
mer or current smokers (Table 1, Fisher’s exact test = 0.010). 
Positive TTF1 immunostaining was present in 84 tumors. No 
statistical relationship was observed between TTF1 immunos-
taining and the major histologic pattern.
Sixteen patients had two or more surgically acquired 
specimens of metastatic lesions that were available for review. 
Details of the size, site, and patterns seen in these specimens 
are presented in Table 2. The major histologic pattern was pre-
served across the different specimens from each patient, but 
the subtype proportions, particularly for the lesser patterns, 
varied. For example, one patient (Table 2, patient 2) with 
resection of one cutaneous and two brain metastases showed 
a major pattern of acinar with mucin adenocarcinoma but the 
lesser patterns of micropapillary and papillary adenocarci-
noma varied in proportion.
Because of the selection criteria used, only two patients 
had previous resection of their primary lung tumor. In both 
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patients, the major pattern observed at the metastatic site was 
concordant with predominant pattern seen in the primary 
tumor (one patient with major solid pattern and one patient 
with major acinar pattern).
Correlation of OS With Major Histologic Pattern
Patients receiving no systemic therapy.
There was no difference in OS when correlated with the 
major histologic pattern in the metastatic site. OS for patients 
with different major histologic patterns was as follows: major 
solid pattern was 4.2 months (95% CI 3.3–7.4 months); major 
acinar pattern was 4.6 months (95% CI 1.5–16.9 months); 
and major micropapillary pattern was 4.7 months (95% CI 
1.5–11.4 months; Table 3, Fig. 2A).
The only significant factor influencing OS was ECOG 
status: median OS ECOG 0 to1 6.3 months (95% CI 4.0–14.1 
months), ECOG ≥2: 3.9 months (95% CI 1.8–6.8 months), 
hazard ratio (HR) 2.1 (1.1–4.0), p = 0.019; Fig. 3, Table 3). 
Analysis stratified according to stage was not possible because 
of the small number of patients with stage III disease (n = 4).
Patients receiving systemic therapy.
Statistically significant differences in OS in patients 
who received systemic therapy were present by the major his-
tologic pattern. Patients with major solid pattern tumor had 
worse OS at a median 9.4 months (95% CI 8.6–12.2 months) 
when compared with patients with major acinar pattern tumor 
at 15.9 months (95% CI 10.7–24.7 months; HR versus solid 
0.32 [0.15–0.68], p = 0.003) and patients with major micro-
papillary pattern tumor at 18.9 months (95% CI 11.6–24.4 
months; HR versus solid 0.34 [0.17–0.69], p = 0.003; Fig. 
2B). No difference in OS was seen between treated patients 
with major acinar and major micropapillary pattern tumors.
No significant differences in OS were identified by the 
presence or absence of each histologic pattern (Fig. 4). There 
was a direction of effect towards longer OS in patients with 
an absence of the solid pattern (solid present [n = 46] versus 
absent [n = 9], median OS 11.6 months [95% CI 9.4–14.3 
months] versus 17.6 months [95% CI 3.4–44.0 months], HR 
2.0 [95% CI 0.98–4.3], p = 0.056).
Correlation of Mutational Profile 
and Major Histologic Patterns
Mutational analysis for EGFR and KRAS mutations 
was successful in all 100 patients. EGFR and KRAS muta-
tions were identified in 13 of 100 tumors (13%) and 32 of 100 
tumors (32%), respectively. EGFR and KRAS mutations were 
mutually exclusive. EGFR mutations occurred most often in 
major micropapillary pattern tumors (6 of 20 [30%]) followed 
by major acinar pattern tumors (4 of 29 [14%]) and were least 
frequent in major solid pattern tumors (2 of 50 [4%]; Fisher’s 
TABLE 1.  Sample Site and Method of Acquisition, with Largest Dimension in Millimeters; Associations Between EGFR and KRAS 
Mutations with Major Pathologic Subtype; Major Pathologic Subtype and Smoking Status; and EGFR and KRAS Mutations with 
Smoking Status
N
Metastectomy Open Biopsy Core Biopsy
(n, Mean, Range) (n, Mean, Range) (n, Mean, Range)
Sample site Brain 30 30, 20 mm, 7–50 mm
Pleura 25 6, 42 mm, 26–58 mm 19, 19 mm, 2–75 mm
Bone/muscle 20 14, 40 mm, 8–80 mm 2, 34 mm, 28–40 mm 4, 16 mm, 11–22 mm
Mediastinum 18 1, 10 mm, N/A 17, 12 mm, 5–30 mm
Chest Wall 7 1, 40 mm, N/A 5, 13 mm, 10–16 mm 1, 17 mm, N/A
n Solid Acinar MPA Papillary
EGFR mutation Positive 13 2 (15%) 4 (31%) 5 (38%) 1 (8%)
Negative 87 48 (55%) 25 (29%) 15 (17%) 0 (0%) Fisher’s exact = 0.006a
KRAS mutation Positive 32 18 (56%) 9 (28%) 5 (16%) 0 (0%)
Negative 68 32 (47%) 20 (29%) 15 (22%) 1 (1%) Fisher’s exact = 0.789 a
n Never Smoker Former Smoker Current Smoker
Major subtype Solid 50 5 (10%) 24 (48%) 21 (42%)
Acinar 29 9 (31%) 5 (17%) 15 (52%)
MPA 20 6 (30%) 5 (25%) 9 (45%)
Papillary 1 1 (100%) 0 (0%) 0 (0%) Fisher’s  
exact = 0.010a
EGFR mutation Positive 13 9 (69%) 4 (31%) 0 (0%)
Negative 87 12 (14%) 31 (36%) 44 (51%) Fisher’s  
exact < 0.001
KRAS mutation Positive 32 1 (3%) 17 (53%) 14 (44%)
Negative 68 20 (29%) 27 (40%) 21 (31%) Fisher’s  
exact = 0.006
aComparison across four histologic groups.
MPA, micropapillary.
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FIGURE 1.  Representative photo-
micrographs of the four histologic 
patterns seen in the metastatic tumor 
deposits (H&E, ×200). H&E, hema-
toxylin and eosin. A, Papillary pattern 
in a station 7 lymph node; (B) micro-
papillary pattern in a brain metasta-
sis; (C) solid with mucin pattern in a 
parietal pleural metastasis; (D) acinar 
pattern in a brain metastasis
TABLE 2.  Histologic subtypes in patients with two or more available samples 
Patient
Chosen Lesion
Major Type Secondary Types
Alternative Lesion(s)
Major Type Secondary TypesSite, Dimension Site, Dimension
1 Femur, 35 mm Acinar Solid, MP Humerus, 20 mm Acinar
2 Brain, 24 mm Acinar Pap, MP Brain, 40 mm Acinar Pap, MP
Skin, surgical scar, 15 mm Acinar MP, Pap
3 Femur, 50 mm Acinar MP, solid Femur, 50 mm Acinar
4 Brain, 19 mm MP Nil Brain, 15 mm MP
5 Femur, 40 mm MP Acinar Femur, 30 mm MP
6 L5 mass, 40 mm MP Pap, solid L5 mass, 45 mm MP
7 Brain, 25 mm MP Pap, solid, acinar Brain, 27 mm MP Solid
Brain, 12 mm MP Solid
Brain, 25 mm MP Solid
8 Pleura, 50 mm MP Pap, acinar Pleura, 25 mm MP Acinar, Pap
9 Brain, 25 mm MP Solid, Pap Brain, 7 mm MP Solid, Pap
10 Mediastinal LN, 15 mm Pap Acinar Femur, 2 mm a
11 Brain, 20 mm Solid MP Brain, 8 mm Solid MP
Mediastinal LN, 4 mm Solid MP
Brain, 10 mm Solid MP
12 Mediastinal LN, 15 mm Solid Acinar, MP Brain, 19 mm Solid Acinar, MP
13 Brain, 25 mm Solid MP Brain, 12 mm Solid MP
14 Brain 12 mm Solid MP, Pap Brain, 9 mm Solid MP, Pap
15 Brain 10 mm Solid Acinar Brain, 4 mm Solid
16 Cervical LN, 16 mm Solid MP, acinar Brain, 7 mm Solid Acinar
The largest dimension of each specimen is recorded in millimeters. Secondary types listed by relative proportion.
aScattered atypical cells only.
Pap, papillary; MP, micropapillary; LN, lymph node.
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exact = 0.006; Table 1). Both patients with major solid pattern 
tumors and EGFR mutations had uncommon variants (patient 
1, exon 18 E709_T710delinsD; patient 9, exon 20 insertion), 
which are associated with resistance to  first-generation EGFR 
inhibitors24 (Table 4). The one major papillary pattern tumor 
harbored a classic exon 21 L858R mutation. All EGFR muta-
tions occurred in never or former smokers and were not pres-
ent in any current smokers (Fisher’s exact p < 0.001; Table 1).
KRAS mutations occurred in major solid pattern tumors 
(18 of 50 [36%]), major acinar pattern (9 of 29 [31%]) and 
major micropapillary pattern (5 of 20 [25%]) tumors (Table 1), 
without a significant relationship found between the presence of 
KRAS mutations and the major histologic pattern (Fisher’s exact 
p = 0.789, Table 1). Thirty-two KRAS mutations were seen with 
the following frequencies: G12C 20 (63%), G12V 4 (13%), 
G12D 3 (9%), G12A 2 (6%), G12L 1 (3%), G13C 1 (3%), and 
TABLE 3.  OS Outcomes
N Survival Months (95% CI) HR (95% CI) p
Systemic therapy 55 13.0 (10.7–16.4)
Major pattern
  Solid 28 9.4 (8.6–12.2)
  Acinar 13 15.9 (10.7–24.7) Vs. solid 0.32 (0.15–0.68) Vs. solid 0.003
  Micropapillary 13 18.9 (11.6 - 24.4) Vs. solid 0.34 (0.17–0.69) Vs. solid 0.003
  Papillary 1 N/A N/A
  ECOG 0-1 43 13.6 (11.1–17.5)
  ECOG 2 or more 12 8.6 (2.8–17.6) 1.66 (0.9–3.2) 0.128
Male 36 13.0 (9.8–17.2)
Female 19 11.9 (8.9–20.1) 1.02 (0.6–1.8) 0.944
Stage III 11 13.0 (8.6–24.4)
Stage IV 44 12.5 (9.5–16.4) 1.56 (0.8–3.1) 0.207
EGFR+ 6 17.5 (10.7 to not reached)
EGFR− 49 12.5 (9.5–15.8) 0.91 (0.4–2.1) 0.827
KRAS+ 17 11.6 (6.5–17.2)
KRAS− 38 13.0 (10.7–17.5) 1.46 (0.8–2.6) 0.209
No systemic therapy 45 4.7 (3.4–7.4)
Major pattern
  Solid 22 4.3 (3.3–7.4)
  Acinar 16 4.6 (1.9–16.9) Vs. solid 1.2 (0.5–2.9) Vs. solid 0.675
  Micropapillary 7 4.7 (1.5–11.5) Vs. solid 0.9 (0.5–1.7) Vs. solid 0.737
  ECOG 0-1 26 6.3 (4.0–14.1)
  ECOG 2 or more 19 3.9 (1.8–6.8) 2.1 (1.1–4.0) 0.019
Male 30 4.2 (3.3–6.3)
Female 15 11.5 (1.9–16.9) 0.5 (0.3–1.03) 0.062
FIGURE 2.  Overall survival (OS) by major histologic subtype. A, Patients not receiving systemic therapy; (B) patients receiving 
systemic therapy.
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G13D 1 (3%). All patients with KRAS-mutant tumors, except one, 
were former or current smokers (Fisher’s exact = 0.006; Table 1). 
There was no relationship between oncogenic mutations, the 
major histologic patterns in tumors and OS, which may reflect 
the small number of patients in our cohort.
DISCUSSION
This study is the first to examine the impact of the his-
tologic pattern present at metastatic sites in lung adenocar-
cinoma according to recommendation in the IASLC/ATS/
ERS classification for small biopsies/cytology specimens.3 
The recommendation states that pathologists should list the 
histologic patterns present in a small biopsy/cytology speci-
men, which may be from the primary site or metastatic site. In 
this study, we followed this recommendation and in addition 
identified the major histologic pattern in each tumor. A rela-
tionship was determined between the major histologic pattern 
at the metastatic site and OS in patients with unresected stages 
III and IV lung adenocarcinoma who received systemic che-
motherapy. Patients with major solid pattern tumor, who had 
received systemic therapy, had significantly shorter OS when 
compared with patients with major acinar and major micro-
papillary pattern tumors. No significant differences were seen 
based on major histologic pattern of tumor in patients who 
did not receive systemic therapy. In addition, we found that 
EGFR mutations are less frequent in major solid pattern tumor 
FIGURE 3.  Overall survival (OS) by performance status 
(ECOG) for patients not receiving systemic therapy. 
FIGURE 4.  Overall survival (OS) by the presence or absence of each pathologic subtype within a specimen. A, Solid pattern; 
(B) micropapillary pattern; (C) acinar pattern; (D) papillary pattern. 
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at metastatic sites in comparison with major micropapillary 
and acinar pattern tumors.
The role of histologic subtypes/patterns in metastatic 
lung adenocarcinoma has previously been examined by 
another group of investigators. In 1989, Sørensen et al. clas-
sified the histologic patterns of adenocarcinoma in small 
biopsies and cytology specimens from either the primary or 
metastatic site in a group of 220 patients enrolled in a clini-
cal trial according to the 1981 WHO classification (20). This 
study demonstrated that the median survival of patients with 
solid pattern tumors was also poor, of the order of 22 weeks; 
however, this failed to reach statistical significance in com-
parison with patients with acinar, papillary, and bronchioloal-
veolar carcinomas, the latter term having been made obsolete 
in the new IASLC/ATS/ERS classification.3 Of note, they 
commented that the bronchioloalveolar carcinoma pattern 
was not seen in any metastatic tumor. There was a sugges-
tion from their data that partial and complete response rates 
to chemotherapy were similar across the different histologic 
subtypes; however, there was a shorter duration of response in 
patients with solid pattern tumors. It is possible that the lack 
of a statistically significant difference in OS seen in the cohort 
from Sørensen et al.18,19 is a reflection of the activity of the 
cytotoxic drugs used at the time (vindesine, lomustine, cyclo-
phosphamide, and methotrexate). Patients in this earlier study 
did not receive the modern platinum based regimens received 
by many of the patients in our cohort. Given the variability in 
chemotherapy regimens and differences in the timing of tumor 
response assessment of patients in our cohort, we were not 
able to look for differences in response rate.
In a more recent publication from 2012, Warth et al.5 
found differences in response to chemotherapy based on 
histologic subtype in patients with resected stages III and IV 
lung adenocarcinoma. They examined the effect of adjuvant 
chemotherapy for any resected stage and/or adjuvant radio-
therapy for resected stages III and IV disease retrospectively 
in a group of patients. They noted a direction of effect toward 
patients with resected solid predominant tumors receiv-
ing greater benefit from postoperative chemotherapy and/or 
radiotherapy compared with patients with resected nonsolid 
predominant tumors. This contrasts with our finding from the 
purely palliative (unresected) setting that patients with major 
solid pattern tumors had significantly shorter OS after sys-
temic chemotherapy in comparison with patients with major 
acinar and major micropapillary pattern tumors. The underly-
ing reasons for this difference are not apparent, but may relate 
to superior efficacy of chemotherapy agents or radiotherapy in 
the microscopic or minimal residual disease setting.
Morphologic heterogeneity is well recognized as one of 
the histologic hallmarks of resected lung adenocarcinoma.2,3,5 
We confirm previous reports that there is also histologic het-
erogeneity in small biopsy specimens of lung adenocarcinoma 
from metastatic sites in patients with stages III and IV dis-
ease.25,26 We demonstrate that solid pattern tumor was the most 
frequent major pattern seen in our cohort of 100 patients, fol-
lowed by major acinar and major micropapillary patterns, with 
only one patient with major papillary pattern tumor. The rela-
tive frequencies of the major patterns in our cohort differ from 
relative frequencies of predominant patterns in curative resec-
tion specimens reported in recent studies4–7,11 focusing on the 
prognostic importance of adenocarcinoma subtypes in resected 
specimens according to the new IASLC/ATS/ERS classifica-
tion. In these latter studies, the frequency of the predominant 
subtype in the primary tumor ranges from 13 to 37.6% for solid 
TABLE 4.  Patients With EGFR Mutations
Patient
Age at 
Diagnosis Sex
Tumor  
Site
Smoking 
History
Major  
Pattern Exon Mutation Amino Acid Change
EGFR Inhibitor Use 
and Response
1 83 F Brain Former Solid 18 E709_T710delinsD c.2127_2129del Nil
2 45 F Pleura Never Acinar 18/20 G719S / T790M c.2155G>A and c.2369C>T Afatinib; six cycles; 
partial response; 
CNS progression
3 51 F Pleura Never MPA 19 E746_750del c.2235_2249del15 Nil
4 68 F Pleura Former MPA 19 E746_L747delinsNY c.2236_2241delinsAATTAT Nil
5 54 F Pleura Never Acinar 19 E746_750del c.2236_2250del15 Nil
6 36 M Bone/muscle Never MPA 19 L747_T751delinsP c.2239_2251del13insC Erlotinib; eight cycles; 
partial response
7 73 F Bone/muscle Never Acinar 19 L747_P753delinsS c.2240_2258del18 Nil
8 44 M Pleura Never MPA 20 S768_D770dup c.2303_2311dup Erlotinib; one cycle; 
unknown
9 66 M Pleura Former Solid 20 H773_V774insTQPP c.2318_2319insCACACAACCCCC Nil
10 55 M Brain Never MPA 21 L858R c.2573T>G Nil
11 64 M Bone/muscle Never MPA 21 L858R c.2573T>G Gefitinb; 14 cycles; 
partial response
12 79 M Pleura Former Acinar 21 L858R c.2573T>G Nil
13 55 M Mediastinum Never Papillary 21 L858R c.2573T>G Erlotinib; six cycles; 
partial response; 
CNS progression
M, male; F, female; CNS, central nervous system; MPA, micropapillary.
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predominant tumors; 13.8 to 45.1% for acinar predominant 
tumors; 2.3 to 10.3% for micropapillary predominant tumors; 
and 4.7 to 40.7% for papillary predominant tumors. We surmise 
that the most likely explanation for this difference is that the fre-
quencies we observed are a function of the metastatic potential 
of each adenocarcinoma subtype. This has recently been exam-
ined by several authors who compared the predominant sub-
type in the primary tumor with histologic patterns in concurrent 
metastases and showed that both micropapillary and solid pat-
terns are more likely to be present in metastatic tumors, despite 
being present as a small percentage in the primary tumor.25,26 
Our cohort only had two patients with resection specimens 
from their primary lung adenocarcinoma. As such, conclusions 
cannot be drawn on the relationship between the primary lung 
adenocarcinoma and its distant metastatic deposits.
The frequency of EGFR mutation (13%) in our cohort 
of 100 patients with unresectable stages III and IV lung ade-
nocarcinoma is low, but consistent with our mostly Western 
population. EGFR mutations were seen mostly in major 
micropapillary and acinar pattern tumors and in the one major 
papillary pattern tumor and were infrequent in major solid 
pattern tumors.
In early stage27 and stage III25 cohorts from North 
America and Australia, respectively, EGFR mutations were 
more frequent in acinar, micropapillary and papillary predomi-
nant subtypes and rare in solid predominant subtypes, similar 
to our cohort of patients with unresectable stages III and IV dis-
ease. This observation is unlikely to hold in Asian populations. 
In some Asian cohorts, a substantial proportion of patients 
with solid predominant early stage tumors harbor EGFR muta-
tions driven by the high prevalence of EGFR mutation in lung 
adenocarcinoma patients from these ethnic groups.28,29
KRAS mutations were fairly evenly distributed across 
all major tumor patterns in our cohort, which is in line with 
results of Motoi et al.2 who found no association with pre-
dominant pattern and KRAS mutation in early stage patients, 
but contrasts with other resected early stage cohorts where an 
association between KRAS mutations and the solid predomi-
nant subtype has been demonstrated.7,25,27 The known associa-
tion of KRAS mutations and EGFR mutations with smoking 
history was reinforced in this study.
As this was the first exploration of the recommendations 
from the IASLC/ATS/ERS classification for subtyping meta-
static lung adenocarcinoma, our findings require validation 
in larger cohorts. The number of patients with tissue samples 
of equivalent size to core biopsies in our study was small. A 
concern may arise that morphologic subtypes observed on 
core biopsies are not representative of the major subtype of 
the tumor. Future studies would need to include such tumor 
samples to allow greater generalizability of results. Although 
survival analysis demonstrated worse outcomes for patients 
with the major solid pattern, the number of patients in both 
the major micropapillary and major acinar groups was small 
(n = 13 each). Pooling of these two subtypes confirms worse 
outcomes for major solid patients (data not shown). The avail-
ability of a larger sample size would allow exploration of 
whether there is a survival difference between major micro-
papillary and major acinar subtypes.
Given the retrospective nature of this cohort, systemic 
therapies and response assessment were not standardized. 
The potential confounding effects of different therapies in our 
study could be addressed by reviewing the effect of adenocar-
cinoma subtypes in the setting of a clinical trial where sys-
temic therapies have been standardized.
It is acknowledged that providing increasing detail in 
histopathologic reports will be time-consuming for clini-
cal pathologists. If others corroborate our findings, the extra 
detail may provide useful information for clinicians as to the 
expected clinical behavior while on chemotherapy. In other 
tumors streams, morphologic findings impact on clinical deci-
sion making (e.g., grading in breast30 and prostate carcinoma)31 
or provide information on the expected clinical behavior and 
response duration on systemic therapy (e.g., pathologic sub-
typing in malignant pleural mesothelioma).32,33 Recognition 
of different biological behavior among lung adenocarcinoma 
subtypes may act as stimulus for further basic research to 
understand the differences and may lead to the discovery of 
novel targets for new therapeutic approaches.
In conclusion, we have used the morphologic subtypes 
described in the IASLC/ATS/ERS classification of adenocar-
cinoma and investigated their clinical relevance at metastatic 
sites. We have demonstrated that the major solid pattern of 
adenocarcinoma at metastatic sites is associated with worse 
OS compared with the major acinar and major micropapil-
lary patterns for patients treated with systemic chemotherapy. 
We have also demonstrated that major solid pattern is asso-
ciated with infrequent EGFR mutations compared with the 
major acinar and major micropapillary patterns in this western 
cohort. No significant association was seen by pathologic pat-
terns with the distribution of KRAS mutations.
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